- Aileron Therapeutics Inc ALRN presented new clinical data at the European Society of Medical Oncology (ESMO21) Virtual Congress 2021 for ALRN-6924, a chemoprotective agent.
- Aileron is developing ALRN-6924 to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects while preserving chemotherapy's attack on cancer cells.
- The Company presented final results from Phase 1b trial of ALRN-6924 in patients with small-cell lung cancer (SCLC) receiving second-line topotecan treatment.
- The data demonstrated ALRN-6924's 'triple-play efficacy' for reducing neutropenia, thrombocytopenia, anemia, and a reduction of platelet and red blood cell transfusions compared to historical controls.
- While chemoprotection effects were observed across all ALRN-6924 dose levels, the 0.3 mg/kg ALRN 6924 dose level given 24 hours before topotecan demonstrated the most robust chemoprotection results.
- None of the patients treated at the 0.3 mg/kg 24 hour ALRN-6924 dose level had a related serious adverse event (SAE).
- At the 0.3 mg/kg 24 hour ALRN-6924 dose level, one patient required a red blood cell transfusion and a platelet transfusion.
- In the topotecan plus placebo arm of a third-party Phase 2 trial, in SCLC patients receiving topotecan (N=28), 41% and 31% received red blood cell and platelet transfusions, respectively.
- Price Action: ALRN stock is down 6.52% at $1.08 during the market session on the last check Thursday.
- Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
